Kyverna Therapeutics, Inc.
KYTX
$8.17
$0.091.11%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | 30.07M | -103.71M | 30.46M | -- |
| Gross Profit | -- | -30.07M | 103.71M | -30.46M | -- |
| SG&A Expenses | 14.77M | 11.29M | 9.27M | 8.27M | 8.59M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 39.56M | 41.37M | 39.28M | 38.73M | 44.41M |
| Operating Income | -39.56M | -41.37M | -39.28M | -38.73M | -44.41M |
| Income Before Tax | -38.32M | -39.73M | -37.80M | -36.79M | -42.08M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -38.32M | -39.73M | -37.80M | -36.79M | -42.08M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -38.32M | -39.73M | -37.80M | -36.79M | -42.08M |
| EBIT | -39.56M | -41.37M | -39.28M | -38.73M | -44.41M |
| EBITDA | -39.12M | -41.02M | -77.20M | -76.30M | -43.90M |
| EPS Basic | -0.63 | -0.66 | -0.80 | -0.85 | -0.97 |
| Normalized Basic EPS | -0.39 | -0.41 | -0.50 | -0.53 | -0.61 |
| EPS Diluted | -0.63 | -0.66 | -0.80 | -0.85 | -0.97 |
| Normalized Diluted EPS | -0.39 | -0.41 | -0.50 | -0.53 | -0.61 |
| Average Basic Shares Outstanding | 60.90M | 60.43M | 47.16M | 43.42M | 43.23M |
| Average Diluted Shares Outstanding | 60.90M | 60.43M | 47.16M | 43.42M | 43.23M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |